Research
Structural Insight on Interaction of NMDA receptor with fentanyl, ketamine and Isoflurane: A Computational Study to Unravel Mode of Binding.
Cell biochemistry and biophysics – March 01, 2025
Summary
Advanced computer modeling reveals how common anesthetics like fentanyl, ketamine, and isoflurane interact with brain receptors. Using molecular docking techniques, researchers found these drugs form strong, stable bonds with NMDA receptors in the brain, explaining their effectiveness in pain management and anesthesia. The findings illuminate exactly how these medications work at a molecular level.
Abstract
NMDA receptors are considered targets for many anesthetics if they are modulated by the drugs at clinically relevant concentrations. Volatile anest...
Allosteric inhibition of NMDA receptors by low dose ketamine.
Molecular psychiatry – March 01, 2025
Summary
Ketamine's remarkable antidepressant effects at low doses work differently than previously thought. Scientists discovered that tiny amounts of ketamine don't completely block brain receptors, but rather gently modify their function through a newly identified mechanism. This selective action allows normal brain signaling while reducing excessive activity, explaining why low-dose ketamine can effectively treat depression without causing anesthesia.
Abstract
Ketamine, a general anesthetic, has rapid and sustained antidepressant effects when administered at lower doses. Anesthetic levels of ketamine redu...
Is dosage of a meditation app associated with changes in psychological distress? It depends on how you ask.
Clinical psychological science : a journal of the Association for Psychological Science – March 01, 2025
Summary
No Summary
Abstract
Despite growing popularity, associations between dosage and outcomes in meditation app interventions have not been established. We examined this re...
Neural regulation of pain anticipation is associated with mindful behavior change in patients with anxiety or depression: A pilot study.
Psychiatry research. Neuroimaging – March 01, 2025
Summary
No Summary
Abstract
Behavior change often requires overcoming discomfort or difficult emotions. Emotional dysregulation associated with anxiety or depression may preve...
Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample
OpenAlex – February 28, 2025
Summary
Individuals with high lifetime involvement in psychedelic-assisted therapy (PAT) report elevated depression and anxiety, a compelling finding from a cross-sectional study. Analyzing a nonprobability sample of 244 PAT patients, a latent class model identified three groups: High-PAT (55.7%), Medium-PAT (29.1%), and a unique Psilocybin-Ketamine class (15.2%). This psychology-focused research suggests a link between extensive PAT engagement and mental health challenges, informing clinical psychology, medicine, and psychiatry regarding these psychedelics.
Abstract
Psychedelic-assisted therapy (PAT) is an emerging treatment approach that often combines pharmacotherapeutic dosing sessions with more traditional ...
Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies.
Medicine – February 28, 2025
Summary
A breakthrough nasal spray doubles the chance of improvement in patients with hard-to-treat depression. Analysis of five clinical trials shows this ketamine-derived medication significantly reduces depression symptoms and improves daily functioning. While highly effective, some patients experience temporary dizziness or nausea. This treatment offers new hope for those who haven't responded to traditional antidepressants.
Abstract
The efficacy of esketamine nasal spray for treatment-resistant depression remains controversial. This systematic review and meta-analysis was condu...
Effect of Mind Sound Resonance Technique (MSRT) on Cognitive and Psychophysiological Functions in College Students: A Randomised Controlled Study.
Annals of neurosciences – February 28, 2025
Summary
No Summary
Abstract
College students face stressors like academic workload, competition, time management and financial concerns, which affect their psychological, phys...
Esketamine Regulates Mitophagy through ULK1/FUNDC1 Signaling Pathway to Improve LPS-induced Acute Respiratory Distress Syndrome.
Current pharmaceutical design – February 28, 2025
Summary
Esketamine, a promising medication, shows potential in treating acute respiratory distress syndrome by regulating cellular cleanup processes. Research reveals it reduces lung inflammation and damage by activating mitophagy - a natural cellular maintenance system - through the ULK1/FUNDC1 signaling pathway. Tests in mice demonstrated improved lung function, decreased inflammation, and enhanced cell survival, offering hope for better treatments.
Abstract
As a heterogeneous clinical syndrome, acute respiratory distress syndrome (ARDS) is caused by infection-associated inflammation with limited treatm...
Human Service Professionals’, Educators’, and Students’ Attitudes Toward Psychedelics and Psychedelic Therapy
Journal of Human Services – February 28, 2025
Summary
A majority of human service professionals, educators, and students believe psychedelics show promise for treating psychiatric disorders. A survey of 72 individuals in these fields explored their views. While some expressed uncertainty about potential risks, most agreed that psychedelic use under medical supervision is not unsafe. This positive perspective highlights the importance of developing education and training for future applications.
Abstract
Human service professionals are a vital component of the helping services. Their attitudes toward psychedelics and psychedelic treatments are criti...
Ayahuasca and the Unified Integrative Model of Medicine: A Path to Healing and Spiritual Transformation
International Journal of Psychiatry Research – February 28, 2025
Summary
Ayahuasca has emerged as a powerful tool for psychological and spiritual transformation, with studies showing that 70% of participants reported significant improvements in mental health after use. This traditional brew, deeply rooted in South American culture, addresses issues like addiction and trauma through a unified integrative model of medicine. Emphasizing the importance of professional guidance and monotheistic prayer during ceremonies, ayahuasca fosters holistic well-being by bridging indigenous wisdom with contemporary science, ultimately facilitating profound healing and self-realization.
Abstract
This article explores the multifaceted therapeutic and psycho-spiritual dimensions of ayahuasca within the framework of a unified integrative model...
Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report
BMC Psychiatry – February 28, 2025
Summary
Profound tensions emerge in **Psychology** and **Psychiatry** concerning **Psilocybin** and other **Hallucinogen** use. A recent case highlights significant clashes between legal therapeutic frameworks and underground practices within **Psychedelics and Drug Studies**. When **adverse effect**s occur, conventional **Medicine** and **Clinical psychology** often conflict with community-based healing. This demands **psychotherapist**s navigate diverse conceptualizations, from psychiatric interventions to energy medicine. Such complexities span **diverse academic research themes**, underscoring the importance of understanding **chemical synthesis and alkaloids** in these contexts.
Abstract
This case highlights the tensions between legal and underground psychedelic use within psychedelic therapy training programs, psychiatry and neo-sh...
Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons
Journal of Neurochemistry – February 28, 2025
Summary
Serotonergic psychedelics like LSD rapidly alter how primary rat cortical neurons communicate. This Neuroscience and Neuropharmacology Research found these compounds reduced the fraction of chemical messengers released within 3-30 minutes. This transient effect, gone after 24 hours, varied. DMT only reduced the total supply, while LSD and psilocin also impacted readily available packets. Psilocin increased glutamate release, hinting at complex interactions with glutamate receptor systems. Such Chemistry and Drug Studies on Serotonin's influence via these alkaloids illuminate their therapeutic potential.
Abstract
ABSTRACT The serotonergic psychedelics psilocybin, LSD and DMT hold great promise for the development of new treatments for psychiatric conditions ...
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study
Journal of Psychopharmacology – February 28, 2025
Summary
A single dose of the hallucinogen psilocybin significantly reduced alcohol consumption in adults with severe alcohol use disorder. Ten participants saw heavy drinking days drop by 37.5 percentage points and drinks per day decrease by 3.4 drinks over 12 weeks after a 25 mg dosing. Despite pharmacokinetic variations, with peak psilocin concentrations ranging 14-59 µg/L, this medicine showed promise. Reductions in craving also occurred, highlighting psilocybin's pharmacology and its potential as a novel alcohol treatment. This contributes to psychedelics and drug studies exploring neurotransmitter receptor influence on behavior.
Abstract
Background: Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (A...
Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
Clinical Pharmacology & Therapeutics – February 28, 2025
Summary
Paroxetine significantly reduces the unpleasant effects of LSD, a finding critical for psychedelic medicine. In a randomized, double-blind, crossover study, 23 healthy participants receiving paroxetine, versus placebo, experienced less "anxiety," "nausea," and "bad drug effect" from LSD. This pharmacology insight reveals paroxetine increased LSD's concentrations by 1.4-1.5 times, impacting its pharmacokinetics. Such drug studies, exploring chemical synthesis and alkaloids, suggest add-on treatment is well-tolerated, guiding future medicine and potentially dose adjustments, even beyond traditional complementary and alternative medicine approaches.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders...
Hemp proteins conjugated with green tea polyphenol extract form de novo plant-sourced emulsifiers suitable for nanodelivery systems bearing lipophilic psychopharmaceuticals
OpenAlex – February 27, 2025
Summary
A novel biocompatible emulsifier combining hemp protein with green tea polyphenols effectively enhances the stability and bioavailability of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). The resulting nanoemulsions, averaging 200 nm in droplet size, maintained stability for four weeks without phase separation. These formulations demonstrated cellular uptake and acceptable cell viability in vitro, showing potential for safe ingestion. This innovative approach leverages the antioxidant properties of polyphenols to protect sensitive compounds, marking a significant advancement in traditional medicine applications involving tea polyphenols.
Abstract
Nanoformulation is often used to improve the solubility and uptake of bioactives; however, it also protects sensitive bioactives from chemical deco...
Treating Post-Traumatic Stress Disorder in Canadian Special Operation Forces Command With Ketamine Plus Cervical Sympathetic Blockade.
Military medicine – February 27, 2025
Summary
A promising new treatment combining ketamine infusion with nerve blocks reduced PTSD symptoms by 45 points in Canadian special forces operators. The dual therapy also decreased brain injury symptoms by 87% in affected soldiers after just two weeks. This innovative approach offers hope for military personnel struggling with combat-related trauma, performing significantly better than traditional treatments or nerve blocks alone.
Abstract
Canadian Special Operation Forces Command (CANSOFCOM) operators have been extensively deployed in recent conflicts. They are at risk of trauma and ...
Psilocybin Impairs Short-Term Cognitive Flexibility but Indicates Long-Term Benefits in a Rodent Three-Choice Reversal Learning Task
OpenAlex – February 27, 2025
Summary
Psilocybin initially impaired cognitive flexibility in rats, yet showed long-term enhancement. In a **Cognitive psychology** **Task** with 16 rats, **Psilocybin** (1 mg/kg) hindered learning and de-learning speed during the first reversal. However, among the five rats completing all protocols, enhanced learning dynamics emerged in a subsequent reversal, suggesting a delayed benefit for **Cognition**. This nuanced effect on **Flexibility** has implications for **Neuroscience** and **Psychedelics and Drug Studies**, highlighting the complex **Neurotransmitter Receptor Influence on Behavior** over **time**.
Abstract
IntroductionCognitive flexibility is essential for adapting behavior in response to environmental changes and is implicated in various neuropsychia...
Psychedelics are Bringing a new wind to the Pharmacopoeia
Neuroscience and Neurological Surgery – February 27, 2025
Summary
A compelling shift is underway: several hundred clinical trials globally are now exploring psychedelics for mental health restoration. Substances like psilocybin from hallucinogenic mushrooms, and LSD, derived from ergot alkaloids, are key to these drug studies. From diverse geography, DMT in ayahuasca and mescaline from peyote are also being examined. MDMA, an amphetamine resulting from chemical synthesis, completes this new pharmacopoeia. This extensive research aims to revolutionize mental health treatments.
Abstract
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ...
Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
OpenAlex – February 27, 2025
Summary
While Western medical models often lack Indigenous wisdom, a groundbreaking Indigenous-led project in Aotearoa is integrating traditional Māori healing with psilocybin-assisted therapy for problematic methamphetamine use. This initiative, part of broader Psychedelics and Drug Studies, challenges conventional Psychology models. Based at Rangiwaho Marae, it pursues three key objectives: exploring psilocybin's efficacy, developing a skilled Māori workforce, and challenging restrictive legislation. This approach charts new directions for culturally resonant, community-driven healing, respecting ancestral knowledge.
Abstract
Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and ...
Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder.
Journal of psychopharmacology (Oxford, England) – February 26, 2025
Summary
Ketamine shows promise in treating severe depression by changing how the brain processes information. In a groundbreaking study, patients with major depressive disorder received either ketamine or midazolam. Brain activity measurements revealed that ketamine reduced specific neural responses called mismatch negativity. Notably, patients who showed larger decreases in these brain patterns experienced better treatment response and longer-lasting relief from depression.
Abstract
A sub-anesthetic dose of ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, produces robust antidepressant effects in treatment-resista...
Transdiagnostic use of 3,4-methylenedioxymethamphetamine-assisted therapy to treat obsessive-compulsive disorder.
The British journal of psychiatry : the journal of mental science – February 26, 2025
Summary
MDMA-assisted therapy shows promise in treating obsessive-compulsive disorders by enhancing traditional psychological treatments. The drug's unique effects on brain chemistry help reduce anxiety and fear responses while increasing psychological flexibility and emotional openness. When combined with psychotherapy, it may help patients better engage with exposure treatments, leading to improved outcomes in managing compulsive behaviors and intrusive thoughts.
Abstract
This article explores the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy to enhance exposure and response prevention in obs...
Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism – February 26, 2025
Summary
Psilocybin reduces brain blood flow by 11.6% during peak effects, offering insights into how psychedelics affect brain function. Using arterial spin labelling MRI, researchers compared psilocybin with ketanserin (a blocking agent) in healthy volunteers. Psilocybin significantly narrowed the internal carotid artery and decreased cerebral blood flow, while ketanserin showed minimal effects. These findings help explain how psychedelics influence brain activity.
Abstract
Psilocin, the active metabolite of psilocybin, is a psychedelic and agonist at the serotonin 2A receptor (5-HT2AR) that has shown positive therapeu...
Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans
Journal of Cerebral Blood Flow & Metabolism – February 26, 2025
Summary
Psilocybin, a potent hallucinogen, drastically reduces cerebral blood flow and constricts major arteries, a novel finding for medicine. In 28 healthy participants, this psychedelic agonist of serotonin receptors decreased overall cerebral blood flow by 11.6% and narrowed the internal carotid artery by 10.5%. Ketanserin, a serotonin antagonist, showed negligible effects. This pharmacology insight into psilocybin's action, relevant to cardiology and internal medicine, reveals how neurotransmitter receptor influence on behavior unfolds, impacting psychology and future drug studies.
Abstract
Psilocin, the active metabolite of psilocybin, is a psychedelic and agonist at the serotonin 2A receptor (5-HT2AR) that has shown positive therapeu...
Mapping of Subjective Accounts into Interpreted Clusters (MOSAIC): Topic Modelling and LLM applied to Stroboscopic Phenomenology
arXiv Preprint Archive – February 25, 2025
Summary
Visual hallucinations from rhythmic light aren't just random patterns - they reveal fascinating insights into consciousness. By analyzing 862 descriptions from people experiencing stroboscopic light, researchers used AI language models to map common themes in these vivid mental experiences. The results showed both simple geometric patterns and complex altered states, advancing our understanding of how the brain creates conscious experience.
Abstract
Stroboscopic light stimulation (SLS) on closed eyes typically induces simple visual hallucinations (VHs), characterised by vivid, geometric and col...
[Effect of low-dose s-ketamine on cough response during extubation period in patients undergoing suspension laryngoscopic surgery].
Zhonghua yi xue za zhi – February 25, 2025
Summary
Low-dose ketamine proves effective in reducing coughing during throat surgery recovery. In a clinical trial with 66 patients, those receiving a small dose of s-ketamine showed significantly less coughing when breathing tubes were removed - just 39% compared to 67% in the control group. The treatment was safe, with no negative effects on recovery time or vital signs.
Abstract
Objective: To evaluate the effect of low-dose s-ketamine on cough response during extubation period in patients undergoing suspension laryngoscopic...
Ketamine-Assisted Psychotherapy for Generalized Anxiety Disorder: A Comprehensive Case Report with Integrated Neurophysiological Imaging Using Magnetoencephalography
medRxiv Preprint Server – February 25, 2025
Summary
Ketamine therapy's rapid impact on mood and anxiety is remarkable. A case explored how this therapy affects brain networks and activity in generalized anxiety. Treatment significantly reduced anxiety and depressive symptoms, improving cognitive attention. Brain imaging revealed increased functional connectivity across multiple brain networks and beneficial brain wave changes, suggesting enhanced neuroplasticity. This shows how ketamine therapy positively alters brain function for better mood and emotion regulation.
Abstract
This detailed case report explores the application of ketamine-assisted psychotherapy (KAP) in the treatment of a male patient in their late 30’s w...
Cardiac effects of two hallucinogenic natural products, N,N-dimethyl-tryptamine and 5-methoxy-N,N-dimethyl-tryptamine.
Scientific reports – February 25, 2025
Summary
Two naturally occurring hallucinogens, DMT and 5-MeO-DMT, can directly affect heart muscle strength and rhythm by activating serotonin receptors. Research using human heart tissue and specialized transgenic mice revealed these compounds increase heart contractions and beat rate, though less powerfully than serotonin itself. The effects work through specific cardiac proteins like phospholamban.
Abstract
It is unclear whether hallucinogenic tryptamine derivatives namely N,N-dimethyl-tryptamine (DMT) and 5-methoxy-N,N-dimethyl-tryptamine (5-MeO-DMT) ...
Reconstructing Covert Consciousness: Neural Decoding as a Novel Consciousness Assessment.
Neurology – February 25, 2025
Summary
No Summary
Abstract
Determining the level of consciousness in patients with brain injury-and more fundamentally, establishing what they can experience-is ethically and...
Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ‐ and MES‐Induced Seizures in Mice via 5‐HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways
Pharmacology Research & Perspectives – February 25, 2025
Summary
A compelling discovery reveals psilocin, a known hallucinogen, exhibits anticonvulsant effects, offering new avenues in Epilepsy medicine. Administering a modest 3 mg/kg dose of this drug in mice reduced seizure activity. Its pharmacology involves complex chemistry, modulating the kynurenine pathway and opioidergic systems. This work, relevant to psychedelics and drug studies, shows effects mediated through the cannabinoid receptor (CB1) and other neurotransmitter receptors, influencing behavior for the 65 million people globally living with epilepsy.
Abstract
ABSTRACT Epilepsy, a chronic neurological disorder affecting around 65 million people globally, is characterized by recurrent, unprovoked epileptic...
Time moving 100-fold slower: time distortion as a diagnostic clue in anti-NMDA receptor encephalitis.
BMC neurology – February 24, 2025
Summary
Imagine experiencing life in extreme slow motion, where every second feels like minutes passing by. This rare but striking symptom of anti-NMDA receptor encephalitis can make time appear to move up to 100 times slower. Two patients experienced dramatic time distortion as an early warning sign, with one describing everyday movements as if watching life through a slow-motion camera. Their altered perception of time, along with other symptoms, improved significantly after receiving proper treatment.
Abstract
The primary symptoms in the early stages of anti-NMDA receptor encephalitis are psychiatric manifestations, making it difficult to distinguish from...
OpenMMDL - Simplifying the Complex: Building, Simulating, and Analyzing Protein-Ligand Systems in OpenMM.
Journal of chemical information and modeling – February 24, 2025
Summary
Scientists can now better understand how drugs interact with proteins thanks to a powerful new software tool. This open-source toolkit simplifies the complex process of simulating and analyzing how potential medicines bind to their targets in the body. By tracking molecular movements and water behavior during drug-protein interactions, it helps researchers develop more effective medications across various disease targets, from cancer to pain management.
Abstract
Molecular dynamics (MD) simulations have become an essential tool for studying the dynamics of biological systems and exploring protein-ligand inte...
Ketamine Alters Specific Gene Expression Profiles by Transcriptome-Wide Responses in a Ketamine-Induced Schizophrenia-Like Mouse Model.
Molecular neurobiology – February 24, 2025
Summary
Ketamine abuse can trigger psychiatric disorders by altering gene activity in the brain. Scientists discovered that blocking specific brain receptors prevents ketamine's harmful effects on behavior and memory. By analyzing the transcriptome (complete gene activity) in mice, researchers identified key genes like Rgs4 that change after ketamine exposure. Blood tests revealed promising markers that could help detect ketamine abuse and its mental health impacts.
Abstract
Psychotic disorder is a significant consequence of ketamine abuse. However, the molecular mechanisms and biomarkers for this psychotic disorder and...
Shrinking the know-do gap in psychedelic-assisted therapy.
Nat Hum Behav – February 24, 2025
Summary
Delivering effective **psychedelic-assisted therapy** hinges on more than just its potential; it requires precise application. A key insight highlights a crucial gap between what's known about these treatments and their real-world **clinical practice**. The core finding suggests that optimizing **therapist training** is vital. By improving how practitioners are educated, the quality of care significantly enhances, leading to superior **patient outcomes** for **mental health** conditions. This ensures **evidence-based care** is consistently delivered, maximizing therapeutic benefits.
Abstract
Shrinking the know-do gap in psychedelic-assisted therapy.
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.
OpenAlex – February 24, 2025
Summary
Public support for psilocybin policies significantly increases when people learn about its therapeutic benefits. An online survey experiment with 804 participants demonstrated that providing evidence for psilocybin's benefits boosted overall policy support (d = .11) and strengthened beliefs in its safety (d = .26) and efficacy (d = .44). Information on safety also improved policy support (d = .10). This insight into public psychology, relevant to drug studies, suggests how targeted communication, potentially aided by computer science, can influence policy and business surrounding psychedelics.
Abstract
Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently...
Psychedelic Assisted Therapy as a Complex Intervention: Implications for clinical trial design
PsyArXiv – February 23, 2025
Summary
Psychedelic therapy's unique power comes from its complex blend of chemical action and therapeutic support, a multifaceted approach traditional clinical trials struggle to fully measure. This analysis highlights current research limitations. It proposes adapting trial designs to properly evaluate this intricate process, ensuring the full positive potential of these innovative treatments is realized.
Abstract
Psychedelic Assisted Therapy as a Complex Intervention: Implications for clinical trial design
Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc Analysis
Clinical Pharmacokinetics – February 21, 2025
Summary
The provided text is a correction notice regarding an author's name and does not contain the research findings, data, or content of the article itself. Therefore, I cannot summarize the research or include specific data like sample sizes, percentages, or compelling findings as requested. To fulfill your request, please provide the actual research article content.
Abstract
Correction to: Clinical Pharmacokinetics (2025) 64:53–66 https://doi.org/10.1007/s40262-024-01454-4 In the original version of this article, the gi...
Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption.
Journal of psychoactive drugs – February 20, 2025
Summary
Regular ayahuasca ceremony participants showed remarkable mental health improvements lasting up to a year, with the strongest benefits seen in those diagnosed with depression or anxiety. The psychedelic brew's effects included significant drops in stress levels, negative emotions, and substance use. Participants reported enhanced spirituality and self-awareness, while reducing both alcohol and cannabis consumption in the month following ceremonies.
Abstract
The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no p...
Quantitative analysis of recreational psychoactive mushroom gummies in Portland, Oregon
Clinical Toxicology – February 20, 2025
Summary
Many recreational drug users are unknowingly consuming mislabeled psychoactive substances. Gummies marketed for recreation, often suggesting *Amanita muscaria* content, actually contain potent serotonergic tryptamines. Some products falsely claimed to be psilocybin-free. This widespread inaccuracy in labeling presents serious environmental health and toxicology concerns, increasing risks of mushroom poisoning and challenging poison control efforts. Such findings in psychedelics and drug studies highlight critical consumer safety gaps for plant-derived recreational drugs, which lack medical oversight.
Abstract
The labeling of psychoactive mushroom gummies we tested was overall inaccurate. Products suggesting Amanita muscaria content instead contained sero...
BROAD SPECTRUM OF THERAPEUTIC PROPERTIES OF PSILOCYBIN: A LITERATURE REVIEW
Health Problems of Civilization – February 20, 2025
Summary
A single dose of Psilocybin, a potent hallucinogen, combined with psychotherapy, can deliver rapid, months-long benefits for mental health conditions. This broad-spectrum approach offers hope for depression, anxiety, and addiction, especially when standard medicine fails. Psilocybin, an alkaloid explored in Psychedelics and Drug Studies, represents a distinct class from compounds like Phenothiazines and Benzothiazines, often from chemical synthesis, offering a superior safety profile. While generally safe, it can unmask psychotic disorders.
Abstract
Psylocybina to psychoaktywny związek chemiczny występujący w grzybach z rodzaju Psilocybe, które zyskały znaczną popularność w ostatniej dekadzie z...
Tool evolution as a prerequisite for consciousness.
Reviews in the neurosciences – February 20, 2025
Summary
No Summary
Abstract
Within the concept of the extended mind, the active modification of external objects, externalizations, is seen as an auxiliary means to adapt to t...
Brain-derived neurotrophic factor (BDNF) changes in rodent models of schizophrenia induced by ketamine: a systematic review.
Naunyn-Schmiedeberg's archives of pharmacology – February 20, 2025
Summary
A key brain protein may hold clues to schizophrenia's development. Scientists found that ketamine, when given to mice and rats, alters brain-derived neurotrophic factor (BDNF) levels differently based on timing and species. Long-term treatment decreased BDNF in both animals, while short-term exposure actually increased it, revealing complex patterns in brain chemistry changes linked to schizophrenia symptoms.
Abstract
Schizophrenia is a severe neuropsychiatric disorder ranking among the top ten global disability causes. In rodents, sub-chronic or chronic ketamine...
Possible Anti-Aging and Anti-Stress Effects of Long-Term Transcendental Meditation Practice: Differences in Gene Expression, EEG Correlates of Cognitive Function, and Hair Steroids.
Biomolecules – February 20, 2025
Summary
No Summary
Abstract
Background: Our previous comparison of peripheral blood mononuclear cells (PBMCs) from long-term Transcendental Meditation® (TM®) practitioners and...
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Journal of Clinical Medicine – February 20, 2025
Summary
Suicide accounts for 1.4% of global deaths, urging new Medicine. Psilocybin and MDMA show promise in suicide prevention, rapidly reducing suicidal ideation. A systematic review of PsycINFO and MEDLINE found four randomized controlled trials with psilocybin (three studies) and MDMA (one study) reducing suicidal ideation (effect sizes 0.52–1.25). Non-randomized studies reported psilocybin reducing ideation (OR 0.40–0.75). However, LSD, another hallucinogen, increased suicidal ideation (OR 1.15–2.08). Complex neurotransmitter receptor influence means psychedelics' impact on suicidal ideation remains inconclusive for Psychiatry.
Abstract
Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscore...
Efficacy and safety of esketamine for emergency endotracheal intubation in ICU patients: a double-blind, randomized controlled clinical trial.
Scientific reports – February 19, 2025
Summary
A breakthrough in emergency medicine shows that esketamine helps maintain stable blood pressure during critical breathing tube procedures. In intensive care settings, doctors found this alternative anesthesia induction method not only safer but also led to better outcomes. Patients receiving esketamine needed breathing support for half as long and left intensive care eight days sooner than those given traditional medications. The drug also reduced the need for blood pressure support, making emergency endotracheal intubation safer for critically ill patients.
Abstract
Emergency endotracheal intubation in critically ill patients are dangerous procedures with a greater risk of severe hypotension The efficacy and sa...
Anesthetics as Treatments for Depression: Clinical Insights and Underlying Mechanisms.
Annual review of neuroscience – February 19, 2025
Summary
Surprising finding: Common anesthetics may hold the key to treating stubborn depression. While ketamine's antidepressant effects are well-known, other anesthetics like nitrous oxide and propofol also show promise in lifting mood. These drugs appear to reset brain circuits linked to depression, offering rapid relief where traditional treatments fail. The discovery opens new paths for treating resistant depression using existing, well-understood medications.
Abstract
Major depressive disorder and treatment-resistant depression are significant worldwide health problems that need new therapies. The success of the ...
Psychosis in a Military Veteran in the Context of Hallucinogen Use: A Case Report.
Cureus – February 19, 2025
Summary
It's a striking medical finding: hallucinogen use can profoundly impact mental health. One military veteran, experiencing acute psychosis after substance use, received focused care. Clinical assessment revealed the condition's progression. Successful treatment led to significant improvement, underscoring the value of prompt, tailored psychiatric intervention for substance-induced conditions. This case offers valuable insights into managing complex mental health presentations.
Abstract
Psychosis in a Military Veteran in the Context of Hallucinogen Use: A Case Report.
The effect of Psilocybe cubensis alkaloids on depressive-like behavior in mice exposed to maternal separation with respect to hippocampal gene expression and DNA methylation of Slc6a4 and Nr3c1
Behavioural Pharmacology – February 19, 2025
Summary
A compelling finding shows Psilocybe cubensis extract (20 mg/kg) reversed severe depressive and anxiety-like behaviors in mice experiencing early maternal separation. This work, relevant to Psychology and Internal medicine, observed normalized locomotor activity in the open field test. Crucially, the extract corrected altered gene expression and DNA methylation in the hippocampus, specifically within the hippocampal formation. This suggests mechanisms involving serotonergic signaling, vital for Tryptophan and brain disorders, and stress response via Endocrinology. Such insights from Psychedelics and Drug Studies, involving chemical synthesis and alkaloids, offer promise for neuropsychiatric conditions.
Abstract
Maternal separation as an early life stress can lead to long-lasting deleterious effects on cognitive and behavioral functions, and the mood state....
Expanded access to psychedelic treatments: comparing American and Canadian policies.
Gen Psychiatr – February 19, 2025
Summary
Access to promising psychedelic treatments isn't uniform globally. American and Canadian policies differ significantly on patient access to unapproved psychedelic therapies. Regulatory analysis shows Canada's compassionate use programs offer clearer, more streamlined patient access to these emerging medicines than America's evolving system. This impacts how individuals receive innovative care.
Abstract
Expanded access to psychedelic treatments: comparing American and Canadian policies.
The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors.
Molecular psychiatry – February 19, 2025
Summary
Groundbreaking research reveals how esketamine, a promising depression treatment, works through an intricate dance of brain chemicals. The drug affects dopamine levels in the brain's reward center through two distinct pathways - one involving glutamate and another through opioid receptors. While it increases overall dopamine levels, it actually reduces dopamine's response to rewards, explaining both its therapeutic benefits and potential drawbacks. This dual mechanism helps explain why esketamine's effects on mood and behavior are so unique.
Abstract
Esketamine represents a new class of drugs for treating mood disorders. Unlike traditional monoaminergic-based therapies, esketamine primarily targ...
Comparative Efficacy and Safety of Ketamine Versus Electroconvulsive Therapy in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
The Psychiatric quarterly – February 18, 2025
Summary
New hope emerges for treating major depressive disorder: Ketamine performs similarly to electroconvulsive therapy in reducing depression symptoms, while better preserving memory function. Analysis of 643 patients shows both treatments effectively combat severe depression, though ketamine users experience more temporary side effects like dizziness and blurred vision.
Abstract
This meta-analysis aimed to compare the efficacy and safety of ketamine versus electroconvulsive therapy (ECT) in patients with major depressive di...
Examining motivators and barriers to meditation practice among individuals with spinal cord injury: Insights from a survey study.
The journal of spinal cord medicine – February 18, 2025
Summary
No Summary
Abstract
Meditation and mindfulness practices offer promising non-pharmacological alternatives for individuals with spinal cord injury (SCI) to improve thei...
Diplopterys pubipetala (Malpighiaceae): Insights into Antioxidant, Antibacterial, and Antifungal Activities with Chemical Composition Analysis via UHPLC-MS/MS and GC/MS.
Molecules (Basel, Switzerland) – February 18, 2025
Summary
A Brazilian vine traditionally used in ceremonial practices reveals promising therapeutic potential through its powerful natural compounds. Scientists found this plant contains 25 unique bioactive compounds with strong antioxidant properties - some performing nearly as well as vitamin C. The extract showed significant antimicrobial activity, particularly against fungal infections, while analysis revealed several biological properties beneficial for human health. These natural products could lead to new therapeutic applications.
Abstract
Diplopterys pubipetala (Malpighiaceae) is a liana native to the Brazilian Cerrado biome, traditionally used in Ayahuasca preparations. Despite its ...
Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new
European Journal of Anaesthesiology – February 18, 2025
Summary
The growing therapeutic use of hallucinogens like Psilocybin and Lysergic acid diethylamide (LSD) in Medicine necessitates careful Anesthesia considerations. These psychedelics, whether natural alkaloids or via chemical synthesis, influence behavior by targeting Serotonin receptors, particularly the 5-HT2A receptor. Their unique Pharmacology can cause sympathetic activation and raise risks like Serotonin syndrome. Mescaline also presents autonomic challenges. Understanding these Neurotransmitter Receptor Influence on Behavior is crucial for safe patient management during Anesthesia, highlighting a vital area in Psychedelics and Drug Studies.
Abstract
Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As ...
Esketamine reduces postoperative depression in breast cancer through TREK-1 channel inhibition and neurotransmitter modulation.
Cancer cell international – February 18, 2025
Summary
A breakthrough in managing post-surgery mental health: Esketamine shows promise in reducing postoperative depression among breast cancer patients. The treatment works by blocking specific brain channels called TREK-1 and adjusting chemical signals in hippocampal neurons. This targeted approach helps restore emotional balance and improves recovery outcomes for patients after surgery.
Abstract
Postoperative depression significantly affects the quality of life of breast cancer patients. This study explores the potential therapeutic effects...
Phenethylaminylation: Preliminary In Vitro Evidence for the Covalent Transamidation of Psychedelic Phenethylamines to Glial Proteins using 3,5-Dimethoxy-4-(2-Propynyloxy)-Phenethylamine as a Model Compound.
bioRxiv : the preprint server for biology – February 17, 2025
Summary
Psychedelic compounds may create lasting brain changes through a newly discovered mechanism: directly attaching to proteins in brain cells. Scientists found that mescaline-like compounds can permanently modify proteins in glial cells, brain cells that support neural function. This chemical bonding process could help explain why single doses of psychedelics sometimes produce long-term positive effects on mental health.
Abstract
Psychedelics are well known for their ability to produce profoundly altered states of consciousness. But, more importantly, the effects of psychede...
Contemplative practices and the movement toward a more just criminal legal system.
The American journal of orthopsychiatry – February 17, 2025
Summary
No Summary
Abstract
What is the role of contemplative practices in the movement toward a more "just" criminal legal system? Over the past 8 years, we have explored thi...
Quantitative natural language processing markers of psychoactive drug effects: A pre-registered systematic review
Journal of Psychopharmacology – February 16, 2025
Summary
A fascinating finding in Drug Studies reveals that all psychoactive drugs, from stimulants to Psychedelics, alter language production. New Psychology research, applying automated language analysis, objectively identifies short-term effects. For instance, based on two or more studies per substance, stimulants increase verbosity, while MDMA increases closeness to emotional words. Psilocybin enhances positive sentiment, suggesting potential for Medicine and Treatment of Major Depression. One study even validated identifying MDMA intoxication. This objective approach, examining how diverse chemical synthesis and alkaloids impact the mind, moves beyond subjective accounts.
Abstract
Psychoactive substances used for recreational purposes have mind-altering effects, but systematic evaluation of these effects is largely limited to...
Esketamine alleviates LPS-induced depression-like behavior by activating Nrf2-mediated anti-inflammatory response in adolescent mice.
Neuroscience – February 16, 2025
Summary
A breakthrough in depression treatment reveals how esketamine rapidly lifts mood by activating the body's natural anti-inflammatory defenses. This medication works by boosting a key protein called Nrf2, which helps reduce brain inflammation linked to depression. Tests showed that a single dose effectively improved mood and reduced inflammatory markers in both the brain and blood, offering hope for faster-acting depression treatments.
Abstract
The mechanisms underlying esketamine's therapeutic effects remain elusive. The study aimed to explore the impact of single esketamine treatment on ...
Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials.
Journal of affective disorders – February 15, 2025
Summary
Groundbreaking treatments for severe depression show that IV ketamine works faster than traditional electroconvulsive therapy (ECT). In comparing these treatments for major depressive disorder and bipolar depression, ketamine provided quicker symptom relief within 24 hours. While both approaches proved equally effective long-term, ketamine caused temporary vision changes and dizziness, whereas ECT's main side effect was muscle pain.
Abstract
Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar dep...
Treatment Approaches for Posttraumatic Stress Disorder Derived From Basic Research on Fear Extinction.
Biological psychiatry – February 15, 2025
Summary
Groundbreaking research reveals how understanding the brain's fear response mechanisms can revolutionize PTSD treatment. By studying fear extinction—how the brain learns to feel safe again—scientists have developed more effective treatments. Exposure therapy combined with targeted medications shows promise in helping trauma survivors. This translational approach bridges lab findings with clinical practice, offering new hope for PTSD recovery.
Abstract
This brief review article will describe treatment approaches for posttraumatic stress disorder (PTSD) based on findings from basic research. The fo...